施贵宝宣布,其口服药物Mezigdomide针对复发或难治性多发性骨髓瘤的Successor-2研究取得积极3期临床试验结果。该研究达到了主要终点,显示患者无进展生存期显著改善。
安全性方面,Mezigdomide表现出可控的安全性特征,与既往研究一致。详细数据将在即将召开的医学会议上公布。
施贵宝宣布,其口服药物Mezigdomide针对复发或难治性多发性骨髓瘤的Successor-2研究取得积极3期临床试验结果。该研究达到了主要终点,显示患者无进展生存期显著改善。
安全性方面,Mezigdomide表现出可控的安全性特征,与既往研究一致。详细数据将在即将召开的医学会议上公布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.